m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02955)
Name
Cysteinesulfonic Acid
Synonyms
Cysteic Acid; 3-Sulfoalanine; 2-amino-3-sulfopropanoic acid; DL-CYSTEIC ACID; 13100-82-8; beta-Sulfoalanine; Alanine, 3-sulfo-; Cysteinic acid; Cysteric acid; Cipteic acid; Cepteic acid; 3024-83-7; CHEBI:21260; C-9550; 2-amino-3-sulfopropanoate; cysteinsaure; Cepteate; Cysterate; Cipteate; Cysteinesulfonate; NSC 254030; (2R)-2-amino-3-sulfo-propanoic acid; L-Cysteic acid, 8; ACMC-209kii; 3-Sulfoalanine, (L)-; 2-Amino-3-sulfopropionate; AC1L19KC; SCHEMBL44030; CHEMBL1171434; 2-amino-3-sulfopro-panoic acid; BDBM85473; CTK8G7889
    Click to Show/Hide
Status
Investigative
Structure
Formula
C3H7NO5S
InChI
1S/C3H7NO5S/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H,7,8,9)/t2-/m0/s1
InChIKey
XVOYSCVBGLVSOL-REOHCLBHSA-N
PubChem CID
72886
TTD Drug ID
D05AMX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
M-phase inducer phosphatase 2 (MPIP2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary M-phase inducer phosphatase 2 (MPIP2) is a therapeutic target for Cysteinesulfonic Acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Cysteinesulfonic Acid through regulating the expression of M-phase inducer phosphatase 2 (MPIP2). [1], [2]
References
Ref 1 METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022 Mar 14;11(1):14. doi: 10.1186/s40164-022-00256-3.
Ref 2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.